ACHILLES THERAPEUTICS PL-ADR (ACHL) Stock News
NASDAQ:ACHL - Nasdaq - US00449L1026 - ADR - Currency: USD
ACHL Latest News, Press Releases and Analysis
Discover the top movers in Tuesday's pre-market session.
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review.
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - ...
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications...
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 – ...
Achilles Therapeutics Announces Strategic Update
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide...
ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024
ACHL stock results show that Achilles Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achilles Therapeutics (NASDAQ:ACHL) just reported results for the second quarte...
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting...
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform...
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the...
ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024
ACHL stock results show that Achilles Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achilles Therapeutics (NASDAQ:ACHL) just reported results for the first quarter...
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host...
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
ACHL stock results show that Achilles Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achilles Therapeutics (NASDAQ:ACHL) just reported results for the fourth quarte...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process...
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with...
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered...
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies...
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 –
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the...
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...